咳嗽变异性哮喘治疗药物的选择

Treatment Options for Cough Variant Asthma

目的:比较酮替芬与孟鲁司特联合美普清、咳喘宁、必可酮喷雾剂等治疗咳嗽变异性哮喘的临床疗效。方法:将符合病例入选标准的120例患者随机分为观察组、对照组,每组60例。两组患者均以美普清口服、咳喘宁片口服、必可酮吸入治疗为基础治疗方案。对照组同时以酮替芬(1 mg/次,2次/d)口服。观察组同时以口服孟鲁司特钠(5 mg/次,每晚顿服)口服。2组均以15周为治疗周期,治疗后评价临床疗效。结果:观察组临床控制率63.33%,总有效率95.00%,对照组临床控制率46.67%,总有效率75.00%,两组临床控制率、总有效率相比差异有统计学意义(P<0.05)。日间症状评分、夜间症状评分两组均较治疗前减少(P<0.05);但观察组下降较对照组更明显,两组差异显著(P<0.05)。一秒用力呼气容积(FEV1),FEV1百分率两组治疗前、后相比差异显著(P<0.05)。治疗后两组相比差异显著(P<0.05)。观察组副反应发生率3.33%;对照组副反应发生率10.00%。两组差异显著(P<0.05)。结论:孟鲁司特与酮替酚均对咳嗽变异性哮喘有治疗作用,孟鲁司特的治疗作用更好。

Objective：To choose a treatment for cough variant asthma with effective drugs,to compare ketotifen with montelukast joint MeipuQing,BDP spray.Method： The inclusion criteria found 120 cases of patients.They were randomly divided into two groups（60 cases each）.Two groups were treated with meipuqing kechuanning ig,and Beclomethasone Dipropionanate Aerosol as basic treatment program.Control group was also given ketotifen（1 mg,2 times a day） orally.Observation group was also given montelukast（5 mg,qn） orally.Two groups were treated for 15 weeks as a course,then to evaluate the clinical efficacy.Result： The clinical control rate was 63.33%,95.00% total efficiency in observation group.Clinical control rate of the control group 46.67%,75.00% total efficiency in control group.The difference in two groups was significantly（P〈0.05）.Daytime symptom scores,nighttime symptom score in the two groups were less than those before treatment 2（P〈0.05）;but the observation group decreased more significant than the control group,group（P〈0.05）.Forced expiratory volume in one second（FEV1） and FEV1% for 2 groups the difference before and after treatment were significant（P〈0.05）.After treatment,2 groups showed significant difference（P〈0.05）.The incidence of side effects in observation group was 3.33%;control group,10.00%.There was significant difference was P〈0.05.Conclusion： Montelukast and ketotifen are effective for cough variant asthma treatment,the therapeutic effect of montelukast is even better.